Efforts to reduce insecticide inputs against plum curculio, , a key pest of apples in eastern North America, include perimeter-row insecticide sprays applied after the whole-orchard petal fall spray to manage dispersing adults and, more recently, insecticide sprays confined to odor-baited trap trees. Entomopathogenic nematodes (EPNs) are virulent to ground-dwelling stages of , and may be applied to the ground underneath trap-tree canopies. Here, we (1) compared the efficacy of the odor-baited trap tree approach with grower-prescribed (=grower standard) sprays to manage populations over a six-year period in seven commercial apple orchards in New England; and (2) assessed the performance of the EPN at suppressing ground-dwelling stages of .
View Article and Find Full Text PDFErwinia amylovora is the causal agent of fire blight, one of the most devastating diseases of apple and pear. Erwinia amylovora is thought to have originated in North America and has now spread to at least 50 countries worldwide. An understanding of the diversity of the pathogen population and the transmission to different geographical regions is important for the future mitigation of this disease.
View Article and Find Full Text PDFPlum curculio, Conotrachelus nenuphar (Herbst), one of the most important pests of apple in eastern and central North America, is usually managed in New England apple orchards by multiple full-block insecticide applications. Efforts to reduce insecticide inputs against plum curculio include using an "attract and kill" approach: odor-baited trap trees deployed in the perimeter row of apple orchards. The standard approach is based on baiting apple trees with two olfactory stimuli, the fruit volatile benzaldehyde and the aggregation pheromone of plum curculio, grandisoic acid.
View Article and Find Full Text PDFBackground: Options for lowering testosterone in patients with prostate cancer include bilateral orchiectomy, oestrogens and luteinising hormone-releasing hormone (LHRH) agonists. LHRH agonists have become widely used in the treatment of prostate cancer.
Roundtable Assembly: In May 2006, a team of experts convened a roundtable assembly to discuss key issues associated with the use of LHRH agonists in the treatment of prostate cancer.